Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 10, 2003

Primary Completion Date

December 19, 2012

Study Completion Date

May 7, 2013

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone

"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."

Trial Locations (1)

90033

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ortho Biotech, Inc.

INDUSTRY

lead

University of Southern California

OTHER